(Q37662650)

21 August 2017

1 reference

title

Safety of triazole antifungal drugs in patients with cancer (English)

1 reference

21 August 2017

0 references

Simon Cronin

1

1 reference

PubMed ID

20035021

21 August 2017

Pranatharthi H Chandrasekar

series ordinal

2

1 reference

PubMed ID

20035021

21 August 2017

language of work or name

English

0 references

publication date

24 December 2009

1 reference

Journal of Antimicrobial Chemotherapy

21 August 2017

1 reference

21 August 2017

65

1 reference

21 August 2017

3

1 reference

21 August 2017

410-416

1 reference

Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents

21 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Prevention of invasive fungal infections in patients with neoplastic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Update on azole antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Therapeutic drug monitoring for triazoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Reduced oral itraconazole bioavailability by antacid suspension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Mortality and cancer incidence among individuals with Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Posaconazole: a broad-spectrum triazole antifungal

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Long QTc interval and torsade de pointes caused by fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Congestive heart failure associated with itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Voriconazole-induced blistering in the setting of graft versus host disease: A report of 2 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Neuromuscular painful disorders: a rare side effect of voriconazole in lung transplant patients under tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Voriconazole-induced neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Hallucinations during voriconazole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

CYP450 pharmacogenetics for personalizing cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Primary prophylaxis with voriconazole in patients receiving induction chemotherapy on the MRC adult acute lymphoblastic leukaemia trial (UK-ALL XII) to avoid itraconazole-enhanced vinca neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Cyclophosphamide metabolism is affected by azole antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Antifungal serum concentration monitoring: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Antifungal therapeutic drug monitoring: established and emerging indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Voriconazole therapeutic drug monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

What is the "therapeutic range" for voriconazole?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

21 January 2018

New antifungal agents

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP464

21 January 2018

Identifiers

DOI

10.1093/JAC/DKP464

1 reference

21 August 2017

1 reference

PubMed ID

20035021